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The clinical management/understanding of brain metastases (BM) has changed substantially in the last 5 years, with key advanc-
es and clinical trials highlighted in this review. Several of these changes stem from improvements in systemic therapy, which have
led to better systemic control and longer overall patient survival, associated with increased time at risk for developing BM. Devel-
opment of systemic therapies capable of preventing BM and controlling both intracranial and extracranial disease once BM are
diagnosed is paramount. The increase in use of stereotactic radiosurgery alone for many patients with multiple BM is an out-
growth of the desire to employ treatments focused on local control while minimizing cognitive effects associated with whole
brain radiotherapy. Complications from BM and their treatment must be considered in comprehensive patient management, es-
pecially with greater awareness that the majority of patients do not die from their BM. Being aware of significant heterogeneity in
prognosis and therapeutic options for patients with BM is crucial for appropriate management, with greater attention to devel-
oping individual patient treatment plans based on predicted outcomes; in this context, recent prognostic models of survival have
been extensively revised to incorporate molecular markers unique to different primary cancers.
Keywords: brain metastases, chemotherapy, stereotactic radiosurgery, surgery, whole brain radiation.
Brain metastases (BM) affect up to one-third of adults with can-
cer and are a significant cause of patient morbidity, anxiety,
and mortality. With 200 000 patients affected each year in
the United States,1,2 a number that is somewhat speculative
since the incidence of metastatic disease is not a reportable
event, and a presumption of increasing incidence, BM represent
an important public health burden that is 10 times more com-
mon than malignant primary brain tumors. Despite this, the BM
population has received less attention, with historical exclusion
from many clinical drug trials, frequent misperceptions about
prognosis by physicians and patients, and the variable involve-
ment of different care providers who may not follow the patient
longitudinally. Management of BM has changed substantially in
the past 5–10 years, with more varied treatments which have a
greater focus on survivorship and mitigating the effects of
treatment. This review provides a summary of key updates
and considerations in the current management of BM for prac-
ticing clinicians.
Incidence
The incidence of BM is believed to be rising in the setting of im-
proved systemic therapies that control systemic disease and
prolong survival but cross the blood–brain barrier (BBB) too
poorly to prevent the brain from becoming a sanctuary site
for metastatic disease. Accurate estimates of population-level
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incidence of BM are difficult to ascertain, as national registries
such as Surveillance, Epidemiology, and End Results capture in-
formation related to initial diagnosis and management of can-
cer but not events that typically occur later in the disease
course, such as the development of BM. Prior reports suggest
that 10%–35% of adult cancer patients develop BM.1 – 4 In
one metropolitan cancer registry from 1973 to 2001, the inci-
dence proportion (IP) of BM across a variety of malignancies
was 10%, defined as the percentage of patients who were di-
agnosed with BM at any point before death, with large differ-
ences according to primary tumor as well as age, gender,
race, cancer stage, and age at cancer diagnosis.4 In that
study, the IP of BM for the 4 most common cancers that metas-
tasize to the brain were lung (20%), melanoma (7%), renal
(7%), and breast (5%), when combining all initial stages to-
gether for a given primary tumor. When examined according
to stage, patients with lung cancer had the highest IP for devel-
oping BM among all patients with a stage I cancer, at nearly
10%, whereas among patients diagnosed with a stage IV can-
cer, melanoma had the highest IP for BM at 37%. The notion
that modern systemic therapies may alter the natural disease
history and risk for BM in different cancers is perhaps most strik-
ingly seen with human epidermal growth factor receptor 2
(HER2)–positive breast cancer,5,6 melanoma,7 and anaplastic
lymphoma kinase gene (ALK) rearranged non-small-cell lung
cancer (NSCLC).8 – 11 In the trastuzumab era, the incidence of
BM among patients with advanced HER2-positive breast cancer
is 40% –50%, although survival following BM has improved
substantially.5,12 In melanoma, where the brain is a frequent
site of metastases, new immune checkpoint inhibitors and
molecularly targeted agents provide survival benefit in sys-
temic disease and may offer CNS control.7 In patients with
ALK-rearranged NSCLC, the CNS is the first site of progression
in 46% of patients treated with crizotinib.11 Despite these re-
markable subgroup findings, the only populations currently
recommended by the National Comprehensive Cancer Net-
work to undergo a screening brain MRI at diagnosis in the ab-
sence of neurologic symptoms are those with advanced
melanoma, most patients with NSCLC, and all patients with
small-cell lung cancer.13
Prognosis
While BM historically have been associated with a dismal prog-
nosis and median survival of,6 months, a combination of ear-
lier diagnosis in some cases, more effective treatments, and
better understanding of which patients may survive for many
months or years has led to improved prognostication tools. Es-
timating prognosis among patients with BM is clinically rele-
vant, as it allows clinicians to recommend treatments that
balance durability of intracranial tumor control with quality of
life (QoL) and side effects of treatment. A landmark recursive
partitioning analysis (RPA) of prognostic factors among 1200
pooled BM patients treated in 3 Radiation Therapy Oncology
Group (RTOG) trials found that KPS, age, and extracranial dis-
ease status were key determinants of survival, with the
longest-surviving group having a median survival of 7.1
months.14 While this RPA was validated and widely used, at
least 5 additional prognostication models were published in
the subsequent 10 years, in an effort to further refine survival
estimates in an era of improving systemic therapies.15 The
prognostic index that has now become the most prominent is
the Graded Prognostic Assessment (GPA), which was originally
developed from a database of nearly 2000 patients with newly
diagnosed BM accrued to 4 RTOG protocols, and later serially
refined to include patients treated across multiple institutions
and to incorporate prognostic factors unique to different can-
cers, resulting in publication of the diagnosis-specific (DS) GPA
in 2012.16 In the DS-GPA, the significant prognostic factors vary
substantially according to the type of cancer and include fac-
tors such as age, KPS, extracranial disease status, number of
BM, and in the case of breast cancer, the molecular subtype
(Fig. 1). Importantly, the stratification of patients by DS-GPA
score within each cancer reveals marked heterogeneity in out-
come, showing the important differences in prognostication for
different subgroups. For example, patients with small-cell lung
cancer with the lowest DS-GPA score were found to have medi-
an survival of,3 months, whereas breast cancer patients with
the highest DS-GPA score had median survival of.2 years. The
DS-GPA is increasingly being used as a stratification tool for clin-
ical trials in BM and continues to be refined with incorporation
of tumor molecular markers for some cancers.17 The impor-
tance of molecular markers in estimating life expectancy was
highlighted in a recent multi-institutional publication regarding
prognostic factors among 90 patients with BM from ALK-
rearranged NSCLC, which found that median overall survival
(OS) after development of BM was over 4 years.18
In addition to prognostication tools, recent literature
describing outcomes among BM patients has highlighted the
importance of considering systemic disease status when coun-
seling patients and selecting treatments. A large Japanese pro-
spective observational study by Yamamoto et al among 1194
patients with 1–10 BM under 3 cm in diameter and KPS≥ 70
who were treated with stereotactic radiosurgery (SRS) alone
found that among the 850 patients who had died as of last
follow-up, 92% died from systemic disease progression, and
not from their BM.19 This finding has been echoed in other re-
cent studies20,21 and runs counter to a common perception
among physicians22 that the development of BM necessarily in-
dicates a grim prognosis, with rapid fatality consequential to
the BM for all patients. In reality, among patients with cancer,
the status of their systemic disease and its responsiveness to
systemic therapy are much more likely to drive mortality out-
comes than the presence of BM in the current era and together
are a key competing risk.23 For the majority of patients with BM,
the lack of effective systemic therapies implies that most suc-
cumb within a few months of BM diagnosis, but an increasing
subset of patients are experiencing longer survival, especially
in the context of improving systemic disease control. In the
DS-GPA model cited above, however, only the presence or ab-
sence of systemic disease was included in the multivariate
analysis used to derive the model, without information regard-
ing whether systemic disease was under control versus pro-
gressing. One retrospective study reported that if this
information was added to the model for breast cancer patients
with BM, dramatic changes in median survival were found com-
pared with those predicted by the DS-GPA model alone,24 and
another group has developed a nomogram incorporating sys-
temic disease status which demonstrates significant heteroge-
neity within each RPA class or DS-GPA score group, allowing for
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more individualized survival estimation.25 Therefore, prognosti-
cation tools continue to be refined and can increasingly help cli-
nicians and patients best select treatments tailored to their
situation.
Role of Whole Brain Radiotherapy
Whole brain radiotherapy (WBRT), including upfront surgery for
a select minority of patients with bulky tumors, used to be the
standard treatment for most patients with BM, given that WBRT
could be initiated quickly, was widely available, treated both
visible and occult BM, and provided symptom palliation.26 Dur-
ing the past 2 decades, SRS has emerged as a common ap-
proach for patients with a limited number of BM, due to the
conformal treatment targeting the metastasis alone, single-
session delivery, minimal delay to continuing with systemic
therapy, and importantly, less cognitive dysfunction. As recog-
nition has grown that WBRT may cause prolonged fatigue and/
or neurocognitive deficits among some patients with BM, there
has been a desire to test whether WBRT can be safely omitted
from the management of patients receiving SRS, and this has
been the subject of 3 randomized trials from 2006 to 2011,
highlighted below. A more recent, unpublished trial focusing
on neurocognitive outcomes after SRS with or without WBRT,
by the Alliance for Clinical Trials in Oncology (N0574), is de-
scribed separately in the “Neurocognition and Quality of Life
after WBRT” section below.27 Collectively, these trials demon-
strate consistent results for patients with a limited number
(≤4) of BM: (i) there is no survival decrement by withholding
WBRT; (ii) high rates of local disease control are achieved with
SRS alone, but local control rates increase further with the ad-
dition of WBRT; (iii) higher rates of new, distant BM are observed
Fig. 1. Diagnosis-specific graded prognostic assessment worksheet to estimate survival from newly diagnosed brain metastases.* Abbreviations:
GPA, Graded Prognostic Assessment; KPS, Karnofsky performance status; ECM, extracranial metastases; LumA, luminal A; LumB, luminal B; GI,
gastrointestinal. Breast cancer subtype definitions: Basal: triple negative. LumA: estrogen receptor (ER)/progesterone receptor (PR) positive,
(HER2) negative. LumB: triple positive. HER2: ER/PR negative, HER2 positive. *Figure reprinted with permission. #2012 American Society of
Clinical Oncology. All rights reserved. Sperduto PW et al: Summary report on the graded prognostic assessment: an accurate and facile
diagnosis-specific tool to estimate survival for patients with brain metastases. Journal of Clinical Oncology, 30(4):419–425.
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among patients receiving SRS alone, necessitating more fre-
quent salvage treatment, though at least one-quarter of pa-
tients who receive upfront WBRT still develop new BM after
WBRT; and (iv) the risk of cognitive dysfunction is lowered,
but not eliminated, when WBRT is withheld.
The Japanese Radiation Oncology Study Group (JROSG) ran-
domized 132 patients with 1–4 BM to SRS alone versus WBRT
(30 Gy in 10 fractions) plus SRS, and found no differences in me-
dian OS between arms (8.0 vs 7.5 mo, respectively) but found
that WBRT significantly decreased both local recurrence (LR)
from 27% to 11% and distant brain recurrence (DBR) from
60% to 35%.28 Similarly, the European Organisation for Re-
search and Treatment of Cancer (EORTC) enrolled 359 patients
with 1–3 BM treated with either SRS or surgery and randomized
them to observation versus WBRT (30 Gy in 10 fractions), with a
primary endpoint of the maintenance of functional indepen-
dence at 6 months.29 Similar to the JROSG trial, the EORTC
study found that median OS was not different between arms
(10.9 vs 10.7 mo) and that WBRT reduced LR at 2 years from
31% to 19% and DBR from 48% to 33%, with no difference in
functional independence. Of note, WBRT added no OS advan-
tage after either SRS or surgery, echoing the findings of the
classic “Patchell” trial of surgery with or without WBRT.30 Final-
ly, a smaller trial at the MD Anderson Cancer Center random-
ized 58 patients with 1 –3 BM to SRS with or without WBRT
(30 Gy in 12 fractions), with the primary endpoint of neurocog-
nitive deterioration at 4 months, defined as a 5-point drop on
Hopkins Verbal Learning Test–Revised (HVLT-R) total recall.31
Early stopping rules were met after results suggested higher
neurocognitive decline in the SRS+WBRT arm (52% vs 24%
for SRS alone). While the addition of WBRT was associated
with lower LR (33% vs 0%) and DBR (73% vs 27%), similar to
the JROSG and EORTC trials, surprisingly the SRS+WBRT arm
was associated with shorter survival, with median and 1-year
OS being 15.2 versus 5.7 months, and 63% versus 21% for
SRS alone versus SRS+WBRT, respectively. This survival result
has been scrutinized by some and attributed to imbalances be-
tween the treatment arms, particularly with regard to discord-
ant systemic disease burden and rates of salvage therapy,
despite randomization; for example, there were 16 deaths
from systemic disease (64%) in the SRS+WBRT group com-
pared with 10 deaths (50%) in the SRS alone group.
Taken together, these 3 trials established that the addition
of WBRT to SRS for up to 4 BM categorically reduces LR in the
original BM sites as well as providing prophylaxis against DBR,
and all 3 trials found no OS advantage to WBRT. Based on
these data, the American Society for Radiation Oncology
(ASTRO) issued a recommendation in September 2014 discour-
aging the addition of WBRT to SRS for patients with limited
BM.32 In 2015, investigators from these 3 trials published addi-
tional analyses using the original trial data, focusing on partic-
ular patient subgroups. First, in a meta-analysis using individual
patient data from 364 patients with 1–4 BM who received SRS
with or without WBRT from all 3 trials, Sahgal et al33 found no
significant OS difference between patients receiving SRS versus
SRS+WBRT in the overall cohort, but the authors reported that
patients aged ≤50 years at the time of treatment had longer
OS when treated with SRS alone. Hazard ratios (HRs) for survival
with SRS alone ranged from 0.46 to 0.64 for age subgroups,50
years, and became statistically insignificant among older
patients. This provocative finding is hypothesis generating and
has raised questions regarding the modeling used given the
small numbers of young patients in these trials (,35 patients
per arm), the lack of restaging to establish the extent of sys-
temic disease prior to protocol entry, and how the competing
risk of systemic disease was handled.34 In contrast to these
data, a secondary analysis by Aoyama et al35 of the original
JROSG trial poststratified according to DS-GPA found that
among the subgroup of 88 patients with NSCLC and 1–4 BM,
those with higher DS-GPA scores (2.5–4.0) had significantly lon-
ger median OS when treated with SRS+WBRT compared with
SRS alone (16.7 vs 10.7 mo, P¼ .03), whereas there was no OS
difference among NSCLC patients with lower DS-GPA scores.
This observation implies that improved brain control with
WBRT, which has been demonstrated in every SRS+WBRT
trial, may translate into an OS advantage specifically among
high DS-GPA patients because they do not die as rapidly from ex-
tracranial progression. However, because of the small patient co-
hort, lack of stratification according to DS-GPA in the original trial,
and treatment era of 1999–2003, prior to several systemic ther-
apy advances that likely impact extracranial and intracranial dis-
ease control, this retrospective study remains provocative but
only hypothesis generating.
In summary, there may be patient subgroups that derive dif-
ferential benefits from SRS versus SRS+WBRT, but for now the
clinical trial data, while underpowered, largely suggest no OS
difference between these 2 approaches, and prospective trials
are required to test hypotheses from the secondary studies
cited above. Clinical controversy remains regarding optimal pa-
tient selection for receipt of SRS alone, SRS+WBRT, and WBRT
alone.36,37 In addition, it should be emphasized that the major-
ity of patients treated in the landmark SRS, WBRT, and surgery
trials for BM cited above were unselected NSCLC patients, and
therefore caution should be applied when generalizing out-
comes about local therapies from these trials to various
subgroups, such as HER2+ breast cancer or ALK-rearranged
NSCLC patients. A summary of several key recent studies exam-
ining survival and functional outcomes after SRS, with or with-
out WBRT, is provided in Table 1.
Stereotactic Radiosurgery Advances
Number or Volume of Metastases
While the landmark randomized trials from the last decade cited
above enrolled patients with up to 4 BM, there has naturally been
interest in the feasibility and outcomes of patients with .4 BM
treated with SRS alone. There is nothing inherently limiting SRS
only to patients with ≤4 BM, but the original randomized trials
were conducted among patients with only limited intracranial
disease, partly due to the belief that patients with many more
lesions would be better served by WBRT or that SRS to so
many lesions may be associated with excess toxicity or technical
limitations. ASTRO published an evidence-based review on the
role of SRS for BM in 2005 which recommended consideration
of SRS for up to 4 BM that were ≤4 cm in size,38 but this was
prior to the publication of the seminal trials reviewed above,
and the 2012 updated ASTRO guidelines39 and 2011 American
Association of Neurological Surgeons/Congress of Neurological
Surgeons guidelines40 do not make explicit recommendations
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Table 1. Select studies of SRS+WBRT for brain metastases
Studya Year Design N Primary Endpoint OS (mo) Functional Outcomes Distant Brain Control
Alliance27 2015 Phase III RCT: SRS+WBRT
1–3 BM
213 Any neurocognitive
decline .1 SD at
3 mo.
SRS+WBRT: 7.5
SRS alone: 10.7
(P¼NS)
Neurocognitive decline at 3 mo
SRS+WBRT: 88%
SRS alone: 62%
(P¼ .002)
SRS+WBRT: 85%
SRS alone: 51%
(P, .001)
[1 y]
EORTC29,67 2011 Phase III RCT: SRS or surgery+WBRT
1–3 BM and stable systemic disease
359 PS≤ 2 at 6 mo SRS+WBRT: 10.9
SRS alone: 10.7
(P¼NS)
Time to PS. 2 mo
SRS+WBRT: 9.5
SRS alone: 10.0
(P¼NS)
Quality of life
Inferior in WBRT arm at isolated
timepoints, but transient
SRS+WBRT: 67%
SRS alone: 52%
(P¼ .023)
[2 y]
MDACC31 2009 Phase III RCT: SRS+WBRT
1–3 BM
58 5-point drop on
HVLT-R total
recall at 4 mo
SRS+WBRT: 5.7
SRS alone: 15.2
(P¼ .003)
Neurocognitive decline at 4 mo
SRS+WBRT: 52%
SRS alone: 24%
(96% Bayesian posterior mean
probability)
SRS+WBRT: 73%
SRS alone: 45%
(P¼ .02)
[1 y]
JROSG28 2006 Phase III RCT: SRS+WBRT
1–4 BM
132 OS SRS+WBRT: 7.5
SRS alone: 8.0
(P¼ ns)
Neurologic decline at 12 mo
SRS+WBRT: 28%
SRS alone: 30%
(P¼ .99)
SRS+WBRT: 53%
SRS alone: 24%
(P, .001)
[1 y]
JLGK19 2014 Prospective observational: SRS alone
1–10 BM
Stratified by 1 vs 2–4 vs 5–10 BM
1194 OS 1 BM: 13.9
2–4 BM: 10.8
5–10 BM: 10.8
(P¼ .78 for 2–4 vs 5 BM)
Neurologic decline at 12 mo
1 BM: 8%
2–4 BM: 9%
5–10 BM: 12%
(P¼ .60)
1 BM: 63%
2–4 BM: 45%
5–10 BM: 36%
(P, .0001 for 1 vs
2–4 BM;
P¼ .067 for 2–4 vs
5–10 BM)
[1 y]
EORTC/JROSG/
MDACC33
2015 Pooled IPD meta-analysis of 3 RCTs:
SRS+WBRT for 1–4 BM
analyzed according to patient age
364 OS Overall
SRS+WBRT: 8.2
SRS alone: 10.0
(P¼NS)
HR for SRS alone vs
SRS+WBRT
Age 35: 0.46
Age 40: 0.52
Age 45: 0.58
Age 50: 0.64
(all P, .05)
Age .50 (P¼ ns)
NR HR for SRS alone vs
SRS+WBRT
Age≤ 50 (P¼NS)
Age 55: 1.67
Age 60: 1.95
Age 65: 2.27
Age 70: 2.65
Age 75: 3.09
Age 80: 3.60
(all P, .05)
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for patients with more than 4 BM. Many centers have offered SRS
to patients with a larger number of BM over the past 10 years
based on retrospective studies suggesting safety and efficacy.
A comprehensive prospective observational study in Japan
among nearly 1200 patients from 23 institutions with up to 10
newly diagnosed BM treated with SRS alone was published in
201419 and provided a helpful benchmark for understanding
outcomes among this patient population. The largest single
BM allowed per the inclusion criteria was ,10 mL in volume
and ,3 cm in maximal diameter, and the total cumulative vol-
ume of all BM had to be ≤15 mL. The study included 208 pa-
tients with 5–10 BM, and this subgroup had a mean
cumulative tumor volume of 3.54 mL (range, 0.02 to 13.90),
63% of whom had controlled systemic disease and 88% of
whom had KPS≥ 80. Baseline characteristics of the 5–10 BM
group were not significantly different from the group with 2–4
BM, aside from slightly higher cumulative tumor volume
(mean, 3.54 vs 3.07 mL), as expected. The principal finding of
the paper was that median OS was similar between the 5–10
BM and the 2–4 BM groups (10.8 mo in both groups), which
was statistically noninferior for the 5–10 BM group, based
upon a noninferiority margin set at the upper 95% CI for an
HR of 1.30. Secondary outcomes analysis demonstrated that pa-
tients with 2–4 BM as well as those with 5–10 BM had similar
2-year rates of neurologic death (5% vs 7%), new brain lesions
(66% vs 72%), and salvage WBRT (10% vs 9%); the only param-
eter that was significantly higher among the 5–10 BM group was
the risk of leptomeningeal dissemination (13% vs 22%). Toxicity
was low and essentially identical between the 2–4 BM and 5–10
BM groups, with no significant differences in neurocognitive out-
come at 4, 12, 24, or 36 months as assessed by the Mini-Mental
State Examination. While not randomized, this large study pro-
vides some evidence of safety and efficacy of SRS alone for pa-
tients with up to 10 BM with a relatively low intracranial disease
volume; of note, details regarding the frequency and costs of im-
aging and treatment were not reported. Additionally, investiga-
tors at the University of Pittsburgh have described their
outcomes of SRS alone for≥10 BM among a group of 61 patients
who had a mean of 13 BM per patient, 62% of whom had re-
ceived prior WBRT.41 They found that survival was superior
among patients with 10–13 BM compared with≥14 BM, but im-
portantly, median survival in the entire cohort was only 4
months. The role of SRS for patients with ≥4 BM is currently
under further study in randomized trials at UC San Francisco/
North American Gamma Knife Consortium,42 and the MD Ander-
son Cancer Center.43
Technical Advances for Multiple Targets
While the increased use of SRS for patients with higher num-
bers of BM is predominantly driven by a desire to avoid side ef-
fects associated with WBRT, it also stems from improved
technology in the past 5–10 years. Modern SRS can be deliv-
ered with increasing speed while maintaining precision and ac-
curacy, which improves procedural tolerability. Standard SRS
delivery has historically entailed placing an isocenter target
within each BM and then setting up and treating each BM
sequentially, which can take several hours to complete for pa-
tients with 5–10 BM for some SRS treatment platforms. In con-
trast, there has been increasing literature and clinicalTa
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experience over the past 5 years of using a single isocenter
within the brain44 – 47 and then using radiotherapy techniques
such as helical tomotherapy and volumetric modulated arc
therapy to deliver dose to multiple BM at the same time.
While this technique relies on precise patient immobilization,
it has the substantial advantage of being able to reduce treat-
ment time for a patient with multiple BM down to minutes,
without sacrificing accuracy or significantly increasing the inte-
gral radiation dose to the brain. For example, in one comparison
of multitarget single-isocenter SRS versus standard sequential
multiple-isocenter SRS using Gamma Knife (GK) among 28 pa-
tients with a mean of 3 BM, modeled median treatment time
for standard GK was over 2 h compared with 20 min with
the single-isocenter technique.46 This expedited treatment
time for single isocenter has also been published by other
groups44 and makes SRS treatment of patients with 5, 10, 15,
or more BM vastly more feasible and tolerable for the patient.
Similarly, several centers are now using volumetric modulated
arc therapy to combine both WBRT and simultaneous hypofrac-
tionated radiation boosts to individual BM within the same in-
tegrated treatment session. This allows for dose escalation to
individual BM, without requiring separate treatment sessions
from the WBRT fractions.48 Ultimately, the decision regarding
whether to employ SRS, WBRT, or both for patients with multi-
ple BM depends on clinician discretion, patient values, and lo-
gistical considerations. The absolute BM number cutoffs are
becoming less crucial in the modern era, as intracranial BM re-
currence and QoL concerns need to be balanced for individual
patients on a case-by-case basis, especially in the setting of
substantial increases in life expectancy from better systemic
control for some subgroups of patients with BM, with a longer
timeframe at risk for treatment sequelae.
Hypofractionation and Resection Cavity Treatment
Given that SRS is typically reserved for BM that are 3 cm or less
in diameter in order to reduce the risk of radiation necrosis (RN)
in surrounding normal tissues, there has been increasing study
of using hypofractionated SRS for larger BM that are not surgi-
cally resected, or BM near sensitive structures such as the optic
nerves and brainstem. Hypofractionated SRS, also referred to as
hypofractionated stereotactic radiotherapy (SRT), typically en-
tails delivery of 3–5 fractions on consecutive or alternating
days, with the rationale that fractionating the treatment allows
increased recovery of nearby normal tissues and may reduce
toxicity. In one survey of CNS radiation oncologists in the United
States, the 2 most common hypofractionation regimens used
were 25 Gy in 5 fractions, and 21 Gy in 3 fractions.49 Retrospec-
tive studies of hypofractionated SRS for BM have demonstrated
a favorable toxicity profile, with ,5% of patients experiencing
acute grade 3 toxicity and 5% developing RN,50,51 lower
than might be anticipated if using single-fraction SRS for
large lesions. However, the optimal dose/fractionation for
hypofractionated SRS/SRT remains undefined, as the local con-
trol at 12 months ranged from 56% to 68% in 2 recent reports
that predominantly utilized 25 Gy in 5 fractions,50,51 suggesting
that further dose intensification may be warranted when using
hypofractionation, and prospective data are lacking.
Finally, there is a rapidly expanding recent body of literature
on outcomes of single-fraction SRS or hypofractionated SRS
targeting the resection cavity after surgical resection of BM52
as a means of avoiding adjuvant WBRT. An initial experience
published by Stanford University in 2008 among 72 patients
observed a 79% local control rate at 12 months, using a medi-
an dose at the margin of the target/cavity of 18.6 Gy.53 Many
retrospective studies have reported local control rates in the
85% –95% range,54,55 and the addition of a 2-mm margin
around the resection cavity has been shown to be associated
with improved local control.56 Some reports have suggested a
higher risk of leptomeningeal dissemination among patients
with breast cancer BM treated with cavity SRS,57 though
other studies have not observed this.58 Hypofractionated SRS
has also been used by many centers for larger surgical cavities
measuring well over 3 cm, with local control found to be similar
to single-fraction SRS.59,60 However, a randomized trial has not
yet been published examining how cavity SRS compares with
adjuvant WBRT after surgical resection of BM, and 2 random-
ized trials are currently ongoing to answer this question with
more statistical rigor. One is from the MD Anderson Cancer Cen-
ter61 and is evaluating local control after either observation ver-
sus cavity SRS following resection of BM. The second is being
conducted through the Alliance for Clinical Trials in Oncology
(N107C)62 and examines OS and neurocognitive function 6
months following adjuvant WBRT versus cavity SRS for resected
BM. In addition, there are emerging data on the use of preop-
erative SRS administered shortly before resection, as opposed
to postoperative SRS, with the goals of improving local control
due to improved targeting of an intact metastasis and reducing
risks of leptomeningeal dissemination and RN. One multi-
institutional retrospective study of 180 patients treated from
2005 to 2013 with SRS before or after resection, 37% of
whom received preoperative SRS within 48 h before surgery,
demonstrated similar rates of local control between those re-
ceiving pre- versus postoperative SRS but significantly higher
rates of leptomeningeal disease (16.6% vs 3.2%, P¼ .01) and
symptomatic RN (16.4% vs 4.9%, P¼ .01) at 2 years among
those receiving postoperative SRS.63 New trials are in develop-
ment that will further compare pre- versus postoperative SRS.
Neurocognition and Quality of Life after
WBRT
Over the past 5 years, there has been accumulating evidence
on deleterious effects patients may experience after WBRT in
particular, as well as new approaches to potentially mitigate
those harms. Most distressing to patients are the risks of neuro-
cognitive decline after WBRT, which was investigated in the MD
Anderson trial31 cited above, but was expanded in the much
larger Alliance N0574 randomized trial27 that was recently pre-
sented at the American Society for Clinical Oncology 2015 An-
nual Meeting. In the Alliance trial, 213 patients with up to 3 BM
received SRS with or without WBRT, with primary endpoint
being cognitive progression at 3 months, defined as a decline
by .1 standard deviation in any of the 6 neurocognitive tests
administered. At 3 months, cognitive decline was observed in
88.0% of patients in the combined arm versus 61.9% in
the SRS-only arm (P¼ .002), including domains such as imme-
diate recall, delayed recall, and verbal fluency. There were no
statistically significant OS differences between arms, though
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intracranial tumor control was higher in the WBRT-containing
arm, as anticipated. Another large recent study that informs
our understanding of the risks of irradiation of the entire
brain was a pooled secondary analysis of 2 randomized trials
evaluating the role of prophylactic cranial irradiation (PCI) in
non-small-cell or small-cell lung cancers, which included 410
patients who received PCI and 173 patients who did not.64
PCI was associated with an approximately 3.5 times higher
risk of decline in self-reported cognitive functioning at both 6
and 12 months compared with patients not receiving PCI
(both P, .001). Objective declines in neurocognitive testing,
as ascertained by the HVLT, were also associated in PCI at
those same time points (both P¼ .002), but intriguingly, corre-
lation between objective decline and self-reported decline was
not significant (P¼ .86 at 12 mo). The clinical findings of cogni-
tive decline following WBRT are echoed in a retrospective study
of 68 patients who survived at least 1 year after treatment:
97% of patients who received WBRT developed white matter
changes on MRI compared with only 3% of those who received
SRS.65
In addition to neurocognition specifically, QoL in general is an
important consideration for patients and physicians in the selec-
tion of treatment for BM. A decline in neurocognition has been
found to precede and predict a deterioration in QoL in this pa-
tient population,66 and thus they are not completely distinct en-
tities. The EORTC published health-related QoL results67 in 2013
on the patients with 1–3 BM enrolled in the SRS or surgery+
WBRT trial29 described above. Patient compliance with QoL re-
cording had dropped to only 45% by 1 year of follow-up, and
thus only the first year after treatment was analyzed. While
QoL scores were generally lower among patients receiving
WBRT in addition to SRS/surgery, the effects appeared to be rel-
atively transient. QoL scores were statistically significantly lower
for global QoL among patients who received WBRT only at 9
months, but not at 2, 3, 6, or 12 months, and similarly were
lower for cognitive functioning at 12 months, fatigue at 2
months, and physical functioning at 2 months, as isolated time-
points. These data could be used to support the contention that
QoL is lower among patients who have received WBRT, but more
importantly show that most patients do not have chronically,
consistently worse QoL globally or within specific domains
after WBRT.
Approaches to Reduce Cognitive Side Effects from WBRT
In an effort to reduce the neurocognitive sequelae of WBRT, 3
recently reported trials have investigated different strategies to
accompany WBRT. Firstly, RTOG 0614 was a Phase III trial inves-
tigating memantine, an N-methyl-D-aspartate receptor blocker
shown to be effective in vascular dementia, and included 508
patients with BM who were randomized to either WBRT plus pla-
cebo versus WBRT plus daily memantine for 6 months.68 The
study narrowly missed meeting statistical significance on the pri-
mary endpoint of less decline in delayed recall at 6 months fa-
voring the memantine arm (P¼ .059), likely a result of patient
mortality with only 280 analyzable patients (55% of enrollees).
The memantine arm did show significantly longer time to cogni-
tive decline (HR 0.78, P¼ .01), with probability of cognitive
decline at 6 months being 54% in the memantine arm and
65% in the placebo arm. Memantine is now being prescribed
to patients receiving WBRT by many providers on the basis of
these data, as both this trial and the Alliance trial of SRS with
or without WBRT27 again highlighted the cognitive side effects
of standard WBRT. However, neurocognitive deterioration is still
quite common among patients with BM, even among the
superior-performing trial arms, with over half of the patients in
the arm receiving memantine (RTOG 0614) and over half of
the SRS-alone treated arm (Alliance) experiencing neurocogni-
tive decline within 3–6 months.
A second strategy to ameliorate the neurocognitive effects
of WBRT has been to use intensity-modulated radiotherapy
(IMRT) treatment planning to develop conformal whole brain
radiation plans that preferentially spare the bilateral hippocam-
pi. This is based on the role of the hippocampus in developing
and preserving memory. RTOG 0933 was a single-arm Phase II
trial that enrolled 113 patients who received hippocampal-
avoidance WBRT for BM and assessed neurocognitive function,
including a primary endpoint of HVLT-R delayed recall at 4
months, compared with a historical control group.21 Only 42
patients were analyzable at 4 months, again highlighting the
challenges to conducting trials among BM patients due to
high mortality. Patients receiving hippocampal-avoidance
WBRT had no measurable decline in QoL and a mean relative
decline in delayed recall score of 7%, which was lower than
the 30% decline seen in the historical control (P, .001). This
study has been considered hypothesis generating and has
not been adopted as standard of care, as it was only a single-
arm study. NRG Oncology has initiated 2 trials to further explore
whether hippocampal avoidance during WBRT decreases the
incidence of neurocognitive sequelae. The first is NRG-CC001,
a randomized Phase III trial examining memantine and
WBRT with or without hippocampal avoidance, with a primary
endpoint of time to neurocognitive decline.69 The second trial
will be NRG-CC003, a randomized Phase II/III trial of PCI with
or without hippocampal avoidance among patients with limit-
ed or extensive stage small-cell lung cancer who achieve at
least a partial remission to chemotherapy.
Finally, a recent multi-institutional trial has investigated the
efficacy of the dementia medication donepezil, to evaluate
whether this neurotransmitter modulator may improve cogni-
tive function among patients who had previously received par-
tial brain RT or WBRT. In the Phase III trial, 198 patients with
primary (n¼ 130) or metastatic (n¼ 68) brain tumors who
were at least 6 months out from brain-directed radiation re-
ceived donepezil or placebo for 6 months.70 Cognitive compos-
ite scores, the primary outcome, did not differ significantly
between the treatment arms, yet significant differences in 2
domains of memory, as well as motor speed and dexterity do-
mains, were statistically improved in the donepezil arm. In all,
the recent trials of memantine, hippocampal avoidance, and
donepezil all showed some improvements in neurocognition
in patients with BM.
Diagnosis and Management of Radiation
Necrosis after SRS
With the growing role of SRS in the management of BM, along-
side advances in systemic therapy leading to longer overall pa-
tient survival, an increasingly common late side effect that
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physicians confront in clinic is the development of RN after SRS.
After high-dose, conformal radiation to the brain such as with
SRS, vascular endothelial cells may become damaged and lead
to fibrinoid necrosis of small arteries, tissue hypoxia, and dam-
age of neurons and glial cells, which is mediated by various cy-
tokines as well as vascular endothelial growth factor
(VEGF).71,72 RN occurs in at least 10% of patients who receive
SRS, typically between 6 and 18 months after treatment, and
is often challenging to distinguish from recurrent/progressive
BM based on conventional MRI given the often similar appear-
ance of both contrast enhancement and edema.73,74 In addi-
tion, radiographic evidence of SRS-induced breakdown of the
BBB without development of an overt necrotic mass, as oc-
curred in 10% of patients in the EORTC trial of SRS with or with-
out WBRT,29 is often referred to as “radiation treatment
change” and may represent early stages of RN. Moderate
doses of corticosteroids such as dexamethasone are often pre-
scribed to control associated neurologic symptoms and/or po-
tentially reduce local inflammation associated with RN. While
the gold standard for diagnosis is surgical resection of the le-
sion, this is not always feasible or desirable, and may show a
mix of RN and tumor. Several recent studies have investigated
the role of various noninvasive neuroimaging approaches to
help distinguish RN from tumor recurrence. These include MR
perfusion75 and dual-phase PET,76 among others. While these
tests can provide adjunctive information, no modality has yet
shown adequate sensitivity and specificity to reliably differenti-
ate these 2 phenomena noninvasively, as acknowledged in the
recently published Response Assessment in Neuro-Oncology–
Brain Metastases (RANO-BM) guidelines.77 Most frequently, cli-
nicians must rely on the pretest probability/clinical suspicion of
RN, and serial MRI over time if the patient is asymptomatic, to
guide management. While standard risk factors for RN include
SRS dose, volume treated, prior irradiation, and chemothera-
py,73 there are growing reports that immunotherapies and tar-
geted systemic therapies that cross the BBB may increase the
risk of RN.78 – 80
Emerging treatments for RN that have published in the past
5 years include bevacizumab and laser interstitial thermal ther-
apy (LITT; otherwise known as laser induced thermotherapy).
Bevacizumab is an antibody against VEGF factor A and was
tested in a small randomized trial of 14 patients who experi-
enced symptomatic brain RN after fractionated radiotherapy
for primary brain or head/neck tumors and were randomized
to either placebo or bevacizumab every 3 weeks for 4 cycles.81
All patients who received bevacizumab had radiographic re-
sponse with reduction in edema and contrast enhancement,
and all had reduction in neurologic symptoms/signs, whereas
no patients receiving placebo had an initial radiographic or
symptomatic response, until the placebo group crossed over
and received bevacizumab, and thereafter all experienced
both radiographic and clinical response. Based on these data
and additional institutional series, bevacizumab can be consid-
ered an option for BM patients without contraindications to its
use, who have progressive symptoms from RN after SRS despite
corticosteroids and are not felt to be good surgical candidates.
However, to improve the evidence base for bevacizumab in the
BM population, there is also an ongoing larger randomized
Phase II study through the Alliance for Clinical Trials in Oncolo-
gy evaluating the efficacy of corticosteroids with versus without
bevacizumab for symptomatic RN specifically after SRS for BM,
which will provide more robust data in an SRS-treated BM co-
hort.82 In contrast to bevacizumab, LITT is an emerging tech-
nology that uses thermocoagulation to destroy inflammatory
cellular infiltrate in the region of RN, and may potentially be
used for RN, progressive BM after SRS, or a combination of RN
and progressive BM, with an evidence base that is small but ex-
panding. Neurosurgeons who perform LITT typically drill a burr
hole or may perform a small open craniotomy and insert a flex-
ible LITT probe until reaching the region of interest, at which
point the probe is heated to the desired range. The lesion
may be biopsied through the same probe, prior to performing
thermocoagulation. Single-institution reports have found excel-
lent outcomes after LITT, with low risks among appropriately
selected cases.83 LITT represents another option for clinicians
to consider for RN depending on availability, if corticosteroids
have failed and full surgical resection of BM that previously re-
ceived SRS is not feasible, especially if biopsy of the lesion is de-
sired for diagnosis as part of the same procedure.
WBRT and Concurrent Systemic Therapy
Randomized trials to date have not demonstrated an OS bene-
fit from adding systemic therapy to WBRT (Table 2).84,85 With
regard to other endpoints such as radiographic response rate,
progression-free survival, and time to neurologic deterioration,
results are mixed. However, toxicity is generally increased when
adding systemic therapy.84 While a recent Phase II study of
concurrent WBRT with erlotinib among NSCLC patients showed
low toxicity rates,86 a larger, randomized Phase III trial (RTOG
0320) reported grades 3–5 toxicity rates of 41%–49% in the
arms receiving either temozolomide (TMZ) or erlotinib concur-
rently with WBRT, compared with 11% receiving WBRT alone.87
It has been speculated that the shorter survival observed
among the 2 concurrent chemotherapy arms of the RTOG
trial may be attributable to higher rates of toxicity, but the
trial was underpowered to prove this assertion. Most studies
of WBRT with concurrent systemic therapy have enrolled lung
cancer patients, and further studies are needed to examine
the role of adding systemic therapy to WBRT across a variety
of malignancies. While TMZ is sometimes administered concur-
rently with WBRT for patients with BM from malignant melano-
ma, the limited prospective data on this subject suggest
minimal benefit.88 In addition, a Phase II randomized trial of
concurrent TMZ with WBRT for patients with BM from breast
cancer showed no improvement in objective response rate,
progression-free survival, or OS.89 Ongoing randomized studies
include a study of WBRT with or without lapatinib for patients
with BM from HER2-positive breast cancer.90,91
Surgery
The role of surgery in the management of BM has evolved over
time and remains a key treatment modality to consider espe-
cially for BM over 3 cm in size or otherwise bulky lesions causing
neurologic symptoms, and when tissue is necessary to estab-
lish a diagnosis. While the increasing availability of SRS may
lead to fewer resections among BM that are borderline in size,
improvements in systemic therapy leading to longer patient
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Table 2. Select trials of WBRT with concurrent systemic agents for brain metastases
Studya Systemic Agent Primary
Cancer
Trial Design N WBRT Dose Primary
Endpoint
Overall
Survival
CNS
Response
Rate
(CR+ PR) in
Evaluable
Patients
Other Outcomes
Guerrieri
et al,
2004161
Carboplatin NSCLC Phase III
randomized
controlled
trial
(stopped
prematurely
due to poor
accrual)
G1: WBRT (N¼ 21),
G2: WBRT+carboplatin
(N¼ 21)
20 Gy in 5
fractions
Overall
survival
G1: 4.4 mo
G2: 3.7 mo
(P¼ NS)
G1: 10%
G2: 29%
(P¼ NS)
Ushio et al,
1991162
Chloroethylnitrosureas
tegafur
Lung Phase III
randomized
controlled
trial
G1: WBRT (N¼ 25)
G2: WBRT+
chloroethylnitrosureas
(N¼ 34)
G3: WBRT+
chloroethylnitrosureas+
tegafur (N¼ 29)
40 Gy in
1.5–2 Gy
fractions
Tumor control G1: 27 wk
G2: 29 wk
G3: 30.5 wk
(P¼ NS)
G1: 36%
G2: 69%
G3: 74%
G1 vs G2
(P¼ NS)
G2 vs G3
(P¼ NS)
G1 vs G3
(P, .05)
Margolin
et al,
200288
Temozolomide Melanoma Phase II single
arm trial
N¼ 31 30 Gy in 3 Gy
fractions
Objective
response
6 mo 10%
Antonadou
et al,
2002163
Temozolomide Lung, breast,
or
unknown
primary
Phase II
randomized
trial
G1: WBRT (N¼ 23)
G2: WBRT+concurrent TMZ
followed by 6 cycles of
adjuvant TMZ (N¼ 25)
40 Gy in 2 Gy
fractions
RR and
neurologic
symptom
evaluation
G1: 7.0 mo
G2: 8.6
mo
(P¼ NS)
G1: OR 67%
G2: OR 96%
(P¼ .017)
Improvement in
neurologic
function in the
TMZ group
Verger et al,
2005164
Temozolomide Multiple
(50%
lung, 15%
breast)
Phase II
randomized
trial
(stopped
prematurely
due to poor
accrual)
G1: WBRT (N¼ 41)
G2: WBRT+concurrent TMZ
followed by 2 cycles of
adjuvant TMZ
(N¼ 41)
30 Gy in 3 Gy
fractions
Neurologic
toxicity
G1: 3.1 mo
G2: 4.5 mo
(P¼ NS)
Response at
30 d
G1: OR 32%
G2: OR 32%
(P¼ NS)
Freedom from
intracranial
progression at
90 d was
improved in the
TMZ group
Continued
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Table 2. Continued
Studya Systemic Agent Primary
Cancer
Trial Design N WBRT Dose Primary
Endpoint
Overall
Survival
CNS
Response
Rate (CR+
PR) in
Evaluable
Patients
Other Outcomes
Sperduto
et al,
201287
Temozolomide or
erlotinib
NSCLC Phase III
randomized
trial
G1: WBRT+ SRS (N¼ 44)
G2: WBRT+ SRS+ TMZ
(N¼ 40)
G3: WBRT+ SRS+ erlotinib
(N¼ 41)
WBRT: 37.5 Gy in
2.5 Gy fractions
SRS dose was size
dependent:
lesions, 2 cm,
2.1 to 3.0 cm,
and 3.1 to
4.0 cm received
24, 18, and
15 Gy,
respectively
Overall
survival
G1: 13.4 mo
G2: 6.3 mo
G3: 6.1 mo
(P¼ NS for
G1 vs G2
and G1 vs
G3)
Not reported No difference
between groups
in time to CNS
progression
Grade 3–5 toxicity
rates were 11%
in G1, 41% in G2,
and 49% in G3;
high toxicity
rates may have
led to inferior
survival in the
combination
arms
Welsh et al,
201386
Erlotinib NSCLC Phase II
single-arm
trial
N¼ 40 35 Gy in 2.5 Gy
fractions
Overall
survival
11.8 mo 86% No grade 4–5
toxicities
Median survival was
19.1 vs 9.3 mo
for patients with
vs without an
EGFR mutation
Knisely et al,
2008
(RTOG
0118)165
Thalidomide Multiple
(60%
lung)
Phase III
randomized
trial
G1: WBRT (N¼ 93)
G2: WBRT+ thalidomide
(N¼ 90)
37.5 Gy in 2.5 Gy
fractions
Overall
survival
G1: 3.9 mo
G2: 3.9 mo
Not reported No difference
between arms in
time to
progression or
rate of death due
to brain
metastases. 48%
patients
discontinued
thalidomide due
to side effects
Neuhaus
et al,
2009166
Topotecan Lung Phase III
randomized
trial
(stopped
prematurely
due to poor
accrual
G1: WBRT (N¼ 49)
G2: WBRT+ topotecan
(N¼ 47)
20 Gy in 2 Gy
fractions
Overall
survival
G1: 95 d
G2: 87 d
(P¼ NS)
Response
2 wk after
treatment
G1: 52%
G2: 60%
No difference
between groups
in progression
free survival
Abbreviations: CR, complete response; PR, partial response; OR, odds ratio. aArranged according to systemic agent and study design.
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survival may be increasing the number of patients with BM
overall, including those requiring surgery. As discussed previ-
ously, results from the EORTC trial of SRS or surgery with or
without WBRT29 echoed those from the classic trial by Patchell
et al30 of surgery with or without WBRT, in that neither study
demonstrated an OS advantage with the addition of WBRT
after surgery. While most clinicians still appropriately recom-
mend radiotherapy (WBRT or cavity SRS) after resection of BM
for improved local tumor control, it is important to recall that
this has not been shown in randomized trials to improve sur-
vival, and there may be patient-specific scenarios where sur-
gery alone followed by surveillance is appropriate.
Other emerging updates with regard to the surgical man-
agement of BM have been cited above, including the increasing
prevalence of postoperative SRS to the surgical cavity, which
avoids WBRT, and investigation of preoperative SRS, which
has been shown in at least one study to have similar local con-
trol as cavity SRS but with higher rates of both leptomeningeal
disease and RN.63 In addition, LITT is a new tool for neurosur-
geons in the management of RN after SRS for BM as highlighted
above, though its evidence base is thin and requires more study
to better establish efficacy and optimal indications.
Systemic Therapy
Challenges in Treating Brain Metastases with Systemic
Therapy
Because active BM often coexist with active systemic disease,
antitumor agents that can control both intracranial and extra-
cranial disease are needed. Unfortunately, few clinical trials of
systemic agents have been conducted to date in patients with
BM, and this population has frequently been excluded from clin-
ical trials of emerging investigational drugs.92 Comparison across
BM trials has also been hampered by clinical trial design includ-
ing enrollment of heterogeneous populations and varying defini-
tions of criteria to assess response and progression. Response
Evaluation Criteria in Solid Tumors (RECIST) for response assess-
ment sums representative target lesions across all organ sites,
including CNS and non-CNS sites. For therapies with differential
responses in CNS and non-CNS locations, RECIST may not ade-
quately describe CNS progression or response. Strong consider-
ation should be given to assessing CNS and non-CNS for
progression as separate compartments. Indeed, RANO-BM is
an international collaboration attempting to address these is-
sues in clinical trial design and radiographic assessment by de-
veloping uniform radiographic response criteria for use in BM
trials.77,93,94 RANO-BM recommends assessing the CNS and
non-CNS sites according to RANO-BM criteria and RECIST, respec-
tively. These radiographic response criteria proposed by
RANO-BM are now being adopted in clinical trials of patients
with BM where the CNS outcomes are important primary objec-
tives. In addition, the Jumpstarting Brain Tumor Drug Develop-
ment Coalition Imaging Standardization Steering Committee
(an international collaboration which includes members of
RANO-BM) recently published consensus recommendations for
a standardized brain tumor imaging protocol in clinical trials.95
BM differ from metastases to other organs from a pathophys-
iologic and clinical perspective.96 The brain has a unique micro-
environment and an immune system distinct from other
organs.96 For example, Zhang et al97 showed that tumor cells
with normal expression of phosphatase and tensin homolog
(PTEN) lose PTEN expression after dissemination to the brain
(but not to other organs) and regain PTEN expression after leav-
ing the brain microenvironment in a process that is epigenetically
regulated by microRNAs from brain astrocytes. BM patients may
also develop neurologic deficits and seizures, which could require
the use of medications (ie, enzyme-inducing anticonvulsants,
steroids) that can interfere with the metabolism of antitumor
agents. These issues in part lead to the perception that BM pa-
tients are less than ideal candidates for early-phase clinical trials.
However, in a review of Phase I clinical trials at MD Anderson
Cancer Center comparing patients with treated, stable BM versus
those without BM, the presence of BM was not an independent
factor for survival, and the time to treatment failure was not dif-
ferent between groups.92 In addition, the incidence of serious
adverse events including neurologic toxicity was not increased
in the BM population. These data suggest that patients with
treated and stable BM should indeed be included in early-phase
clinical trials.
Another way that BM differ from metastases to other organs is
the presence of the BBB, which is a specialized cellular barrier that
prevents macromolecules from entering the brain and can effi-
ciently pump out unwanted compounds through efflux trans-
porters such as P-glycoprotein and the breast cancer resistance
protein (ATP-binding cassette subfamily G member 2).98 This is
best demonstrated by targeted agents associated with good sys-
temic control but insufficient CNS control, such as trastuzumab in
HER2-positive breast cancer99 and crizotinib in NSCLC with
ALK-gene rearrangement.100,101 Intrathecal chemotherapy can
deliver drug directly to the CSF but cannot reliably treat parenchy-
mal disease or even bulky leptomeningeal disease, as diffusion of
drug into tumor deposits thicker than 1 mm, along nerve root
sleeves, and into the Virchow–Robin spaces is limited.102,103
The BBB in BM is somewhat disrupted, as demonstrated by
leakage of gadolinium enhancement into the tumor on brain
MRI. However, there is debate about how disrupted the BBB is
and whether we can rely on this disruption (however minimal)
to permit sufficient drug penetration. For example, mouse
models of BM suggest that penetration of lapatinib, a HER2-
directed tyrosine kinase inhibitor (TKI), is variable between
and within metastases, with some lesions demonstrating
very high levels of lapatinib (17% freely permeable) and others
not statistically distinct from normal brain.104 The degree of
drug penetration was not well correlated with lesion size. Sim-
ilar findings were obtained in a prospective clinical study of
capecitabine and lapatinib uptake in surgically resected BM
from 12 breast cancer patients.105 Detectable levels of capeci-
tabine or lapatinib were found in resected tumor tissue, but
drug distribution was widely variable among patients. In anoth-
er experimental model of breast cancer, BM uptake of
14C-paclitaxel and 14C-doxorubicin was generally greater than
normal brain but ,15% of that of other tissues or peripheral
metastases and reached cytotoxic concentrations in only a
small subset (10%) of the most permeable metastases.104
Attempts to improve drug delivery across the BBB include in-
hibition of drug efflux transporters, pulsatile dosing regimens,
and BBB disruption with ultrasound, although these strategies
remain in clinical development.106 ANG1005 combines pacli-
taxel with an amino acid peptide that targets the lipoprotein
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receptor-related protein 1 receptor (which mediates transcyto-
sis on endothelial cells of the BBB and mediates endocytosis on
multiple tumor cells). A Phase II study of ANG1005 in breast
cancer patients with BM demonstrated antitumor activity in
the CNS with radiographic response rates of 22%–40%.107 Es-
calating dosing of the epidermal growth factor receptor (EGFR)
TKIs gefitinib and erlotinib may increase CNS penetration.108
Pulsatile dosing of erlotinib at 1500 mg once weekly is associ-
ated with a CSF concentration of 130 nM, sufficient to inhibit
50% growth in cancer cell lines.109 A retrospective analysis sug-
gested that pulsatile dosing is well tolerated and effective in
patients with EGFR-mutant lung cancers with CNS metastases
(parenchymal and leptomeningeal) even after progression on
standard dosing erlotinib.110
Some antitumor agents are not dependent on whether they
can cross an intact or even variably disrupted BBB—for in-
stance, immune checkpoint blockade therapies such as the cy-
totoxic T lymphocyte antigen (CTLA)–4 antibody ipilimumab,
which relies on activated T cells in the periphery to migrate
into the CNS, as well as angiogenesis inhibitors such as bevaci-
zumab, which need reach only the luminal side of the vascular
wall. Both of these agents have demonstrated activity in BM
and, as detailed above in the case of bevacizumab, against
RN resulting from prior SRS. Of note, both ipilimumab and bev-
acizumab are monoclonal antibodies and are generally consid-
ered too large to cross an intact BBB. Nonetheless, ipilimumab
has activity in BM from melanoma.7 In a Phase II trial of ipili-
mumab in metastatic melanoma patients who were either
neurologically asymptomatic (n¼ 51) or symptomatic and on
a stable dose of corticosteroids (n¼ 21), the median OS was
7 months and 3.4 months, respectively.111 The FDA’s expanded
access program reported 1-year survival rates of 20% in mela-
noma patients with stable, asymptomatic BM treated with ipi-
limumab 10 mg/kg.112 In Italy, an ongoing randomized Phase
III trial is examining the benefit of adding fotemustine or the
anti–programmed cell death protein 1 (PD1) agent nivolumab
to ipilimumab in patients with BM from metastatic melano-
ma,113 and 2 other trials, based in the US and Australia, are
also testing combination nivolumab plus ipilimumab in mela-
noma metastatic to the brain.113,114
Due to concerns for CNS hemorrhage, BM patients were ex-
cluded from early trials of bevacizumab.115 However, analysis
of datasets from bevacizumab clinical trials demonstrated low
rates of CNS hemorrhage in patients with CNS metastases.115
In patients with occult CNS metastases enrolled in random-
ized controlled Phase II/III trials, 3 of 91 bevacizumab-treated
patients (3.3%) developed grade 4 cerebral hemorrhage,
while 1 of 96 control patients (1.0%) developed a grade 5
cerebral hemorrhage. The inclusion of bevacizumab with stan-
dard cytotoxic agents has since been associated with durable
response rates in BM from breast cancer116 and in asymptom-
atic, untreated BM from nonsquamous NSCLC.117 In the latter
patient population, bevacizumab plus carboplatin and pacli-
taxel demonstrated an intracranial response rate of 61.2%
and an extracranial response rate of 64.2% with an accept-
able safety profile with only one grade 1 intracranial hemor-
rhage.117 There is an ongoing randomized Phase III trial
examining the addition of bevacizumab to cisplatin and
pemetrexed as first-line therapy for patients with asymptom-
atic BM from NSCLC.118
Finally, targeted treatments of BM are often based on the
molecular profiles of the primary tumor, as opposed to the
BM itself. However, recent studies comparing molecular profiles
of matched BM and primary tumors demonstrate that somatic
alterations in the BM are frequently discordant with those in the
primary tumor.119 – 121 Brastianos et al120 performed whole-
exome sequencing of 86 matched BM and primary tumors
(mainly breast, lung, and renal cell cancers) and found that
53% of BM harbored a potentially clinically actionable somatic
alteration not detected in the matched primary tumor. The
brain microenvironment may play an important role in driving
some of these alterations. These data suggest that for clinical
trials of targeted agents in BM, biopsy or surgical resection of
BM may be indicated for molecular profiling.
Chemoprevention of Brain Metastases
In cancer patients with a high risk for CNS relapse, interest in
pharmacologic prevention of BM (using the same classes of
agents with proven activity either systemically for that cancer
or in primary brain tumors) is growing.122 Such a strategy may
prevent brain recurrence while preserving neurocognition and
QoL.123 In preclinical mouse models of brain-tropic breast can-
cer, TMZ administered 3 days after inoculation prevented the
formation of experimental BM from cells negative for
O6-methylguanine-DNA methyltransferase.124 In a retrospec-
tive study of patients with EGFR-mutant advanced NSCLC, the
risk of CNS progression initially treated with gefitinib or erlotinib
is lower compared with upfront chemotherapy.125 These data
suggest a role for chemoprevention of CNS metastases in spe-
cific patient populations.
Chemoprevention strategies have been preliminarily tested
in clinical trials. While these studies have not met their primary
endpoints of preventing BM, they are informative for future
study design. The CEREBEL study was a Phase III, randomized
trial of lapatinib+ capecitabine versus trastuzumab+ capeci-
tabine for prevention of CNS metastases.126 Unfortunately,
the study was closed early and was inconclusive for its primary
endpoint. Twenty percent of patients failed screening due to
asymptomatic BM on brain MRI at study entry. The 3% and
5% rates of CNS as first site of relapse with lapatinib+ capeci-
tabine and trastuzumab+ capecitabine, respectively, were far
lower than the expected rates of 12% and 20%, respectively;
these expected rates were based on historical trials in which
baseline CNS imaging was not required (and hence likely includ-
ed a substantial number of patients with occult BM who then
had a higher likelihood of progression in the brain during the
course of the trial). Therefore, the study was underpowered
for its primary endpoint. A Phase II randomized study of main-
tenance TMZ versus observation for prevention of BM in high-
risk NSCLC was also closed early with 53 patients enrolled.123
There was no difference in the incidence of BM at one year
(18% in the TMZ arm and 13% in the observation arm, P¼
.6995). Again, the incidence of BM was lower than expected
(13% in the observation arm vs the 40% predicted based on
historical data). Furthermore, TMZ prophylaxis is unlikely to be
effective in view of its overall very low antitumor activity against
NSCLC in general. Future chemoprevention efforts will need to
be redesigned based on improved agents, a better understand-
ing of the populations at risk for CNS relapse, pharmacokinetics
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and pharmacodynamics, the emergence of improved imaging
methods, and a better understanding of the safety of combin-
ing systemic therapy with radiotherapy. For the present and the
foreseeable future, the best form of prophylaxis against BM will
continue to be the discovery of agents and strategies with in-
creasing overall activity against each type and subset of cancer.
Tumor-Specific Systemic Therapies for Brain Metastases
Guidelines from the National Comprehensive Cancer Network
for management of BM recommend local radiation or surgery
as upfront treatment.127 Indeed, no chemotherapy is approved
by the US FDA for management of BM from breast cancer, lung
cancer, melanoma, or other solid tumors, and none of the
available systemic therapies are generally considered first-line
treatment for BM.128 Nonetheless, in a few select patients
with asymptomatic or minimally symptomatic BM, treatments
with established efficacy in BM may be reasonable to consider
as initial therapy.
In breast cancer patients, the risk of developing BM and sur-
vival after BM diagnosis vary according to tumor subtype.99,129
In patients with triple negative breast cancer, the risk of CNS re-
lapse may be as high as 46%, and CNS involvement often oc-
curs in the setting of active systemic disease.99 This high rate of
CNS involvement is unlikely to be due to a sanctuary effect, but
rather to the lack of effective therapies in general for this ag-
gressive subtype of breast cancer.23 In breast cancer patients
with HER2-positive disease, up to 40%–50% will develop BM,5
often despite controlled systemic disease.99 Some studies sug-
gest that up to half of HER2-positive patients die of BM-related
causes,130 emphasizing the importance of CNS control in this
patient population. For the HER2-positive patient population,
the American Society of Clinical Oncology offers recommenda-
tions on the management of BM.6 Clinical trials of lapatinib in
combination with capecitabine have demonstrated activity
with a CNS objective response rate of 20% in patients with pre-
viously treated BM131 and 66% (using a volumetric response
criteria) in patients with previously untreated BM132 (Table 3).
More recent trials in the HER2-positive population with BM
have examined the potential benefit of other HER2-directed
TKIs. Afatinib (alone or in combination with vinorelbine)133
did not demonstrate efficacy over investigator’s choice for
management of BM in HER2-positive patients and was not as
well tolerated. Single-agent neratinib had low efficacy in previ-
ously treated BM with a CNS objective response rate of only
8%,134 but neratinib in combination with chemotherapy may
prove more efficacious. In the NEfERT-T trial for untreated met-
astatic HER2-positive breast cancer (including women with
asymptomatic CNS metastases), the neratinib+ paclitaxel
arm had a lower incidence of CNS recurrences and delayed
time to CNS metastases compared with trastuzumab+ pacli-
taxel.135 However, these results require validation in a larger
study. Other promising agents in clinical trials for breast cancer
patients with BM include trastuzumab+ emtansine (for HER2+
disease),136 pathway inhibitors of phosphatidylinositol
3-kinase–mammalian target of rapamycin, CDK4 inhibitors,
and poly(ADP-ribose) polymerase inhibitors.137
For melanoma patients, up to 60% will develop BM during
the course of their illness.7 Ipilimumab111 (as previously dis-
cussed) or BRAF inhibitors such as dabrafenib138 (for patients
with BRAFV600 mutations) can be considered for management
of progressive BM (Table 3). A Phase II study of dabrafenib in
patients with Val600Glu or Val600Lys BRAF-mutant melanoma
and previously untreated BM (n¼ 89) or treated BM (n¼ 83)
demonstrated remarkable median OS of 33 weeks and 31
weeks, respectively.138 In a Phase III randomized study of
704 patients with BRAF-mutant metastatic melanoma that al-
lowed patients with stable, treated BM, the combination of a
BRAF inhibitor and an inhibitor of mitogen/extracellular signal-
regulated kinase (MEK) demonstrated superior progression-free
survival and OS compared with a BRAF inhibitor alone.139 The
efficacy of combination therapy with a BRAF inhibitor and a
MEK inhibitor for treatment of BRAF-mutant melanoma BM is
now being evaluated in 2 Phase II studies.140,141 Anti-PD1
checkpoint inhibitors such as nivolumab and pembrolizumab
are also under investigation for BM from metastatic melanoma.
Preliminary evidence from a small prospective series suggests
that pembrolizumab may be active against melanoma meta-
static to the brain and may be less toxic than ipilimumab.142,143
The combination of ipilimumab and nivolumab has shown en-
hanced activity in systemic metastases of melanoma, albeit at
the cost of increased immune-related toxicity.144,145 Nonethe-
less, this strategy of combining anti –CTLA-4 and anti-PD1
agents is also undergoing evaluation in several prospective
studies for melanoma patients with BM.113,114
The options for NSCLC patients with BM may include peme-
trexed146 or an EGFR TKI such as gefitinib147 or erlotinib148 (for
patients with activating EGFR mutations) (Table 3). Response
rates of BM to EGFR TKIs at conventional doses in patients
with EGFR-mutant NSCLC may be as high as 60%–80%.149 As
previously mentioned, pulsatile dosing of erlotinib administered
once weekly can be an effective strategy for management of
BM even in patients who have progressed on daily erlotinib.110
For the 2%–7% of NSCLC patients who harbor ALK-gene rear-
rangements, CNS metastases are a relatively common compli-
cation and represent a major barrier to achieving long-lasting
disease control.149,150 In a Phase III randomized trial of the
ALK inhibitor crizotinib, 35% of patients with ALK-rearranged
NSCLC had BM at the time of study entry.151 Based on pooled
analysis of 2 large clinical trials of crizotinib in patients with
ALK-rearranged advanced NSCLC, 20% of patients without BM
at baseline and 70% of patients with known BM developed CNS
progression while on crizotinib.8 Second-generation ALK inhibi-
tors with increased potency such as alectinib and ceritinib may
have better CNS penetration. Preclinical pharmacokinetic stud-
ies of alectinib demonstrate improved CNS penetration over cri-
zotinib, with CNS concentrations 63%– 94% of serum
concentrations.152 In Phase I studies of alectinib or ceritinib
that allowed patients with CNS metastases and no prior brain
radiotherapy at study entry, 3 of 4 patients with measurable
CNS disease in the alectinib study and 6 of 11 patients with
measurable CNS disease in the ceritinib study achieved a com-
plete or partial CNS response.153,154 In a separate study of alec-
tinib for crizotinib-resistant ALK-rearranged NSCLC that allowed
stable, treated, or asymptomatic untreated BM at baseline, the
CNS response rate in the 35 patients with measurable CNS dis-
ease was 57%.155 At 12 months, the cumulative CNS progres-
sion rate (24.8%) was lower than the cumulative non-CNS
progression rate (33.2%) for all patients. Ongoing trials of
second-generation ALK inhibitors for BM in ALK-rearranged
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Table 3. Select trials of systemic agents for brain metastases according to primary cancer
Study Systemic Agent Mechanism of
Action
Population Prior Treatment for
BM?
Trial Design N Primary endpoint CNS Response
Rate (CR+ PR)
Overall Survival
Melanoma
Margolin et al,
Lancet Oncol
2012111
Ipilimumab CTCL-4 inhibitor Melanoma
metastatic to
brain
41%–48% had
received prior
brain irradiation
(WBRT or SRS)
Phase II 72 total: 51 in
cohort A:
neurologically
asymptomatic
(N¼ 51)
Cohort B:
symptomatic
(N¼ 21)
Disease control
(CR, PR, SD) at
12 wk¼ 18% in
A and 5% in B
16% cohort A,
5% cohort B
7.0 mo in
cohort A
and 3.7 mo
in cohort B
Long et al,
Lancet Oncol
2012138
Dabrafenib BRAF inhibitor Val600Glu or
Val600Lys BRAF
mutant
melanoma
metastatic to
brain
Cohort A
previously
untreated BM.
Cohort B prior
local therapy
(surgery, WBRT,
SRS)
Phase II 172 total: 89 in
cohort A and
83 in cohort B
Intracranial
response
(CR+ PR)
Val600Glu
39.2% cohort A,
30.8% cohort
B. Val600 Lys
6.7% cohort A,
22.2% cohort B
Val600Glu 39.2%
cohort A,
30.8% cohort
B. Val600 Lys
6.7% cohort A,
22.2% cohort
B
Val600Glu
33.1 mo
cohort A,
31.4 mo
Cohort B
Val600Lys
16.3 mo
cohort A,
21.9 mo
cohort B
Breast Cancer
Lin et al, CCR
2009131
Lapatinib HER2 inhibitor HER2+ breast
cancer
metastatic to
brain
All previously
treated with
brain irradiation
(WBRT or SRS)
Phase II 242: 95 in cohort
A (ECOG 0–1
and 1–2 prior
trastuzumab
regimens) and
147 in cohort B
(ECOG 2 and/or
.2 prior
trastuzumab
regimens)
CNS objective
response (50%
or greater
volumetric
reduction)
6% in cohort A
and cohort B
6.4 mo (cohort
A 9.6 mo,
cohort B
5.5 mo)
Lapatinib+
capecitabine
HER2 inhibitor
(lapatinib) and
prodrug that
converts to
5-fluorouracil
(capecitabine)
HER2+ breast
cancer
metastatic to
brain
Extension phase
for patients on
study who
progressed on
lapatinib
Phase II Subset of 50
patients in
above study
CNS objective
response (50%
or greater
volumetric
reduction)
20% Not reported
Bachelot
Lancet Oncol
2013
LANDSCAPE132
Lapatinib+
capecitabine
HER2 inhibitor
(lapatinib) and
prodrug that
converts to
5-fluorouracil
(capecitabine)
HER2+ breast
cancer
metastatic to
brain
Untreated (no
prior WBRT, SRS,
capecitabine, or
lapatinib)
Phase II 45 CNS objective
response rate
(CR+ PR)
49% 17 mo
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Table 3. Continued
Study Systemic Agent Mechanism of
Action
Population Prior Treatment for
BM?
Trial Design N Primary endpoint CNS Response
Rate (CR+ PR)
Overall Survival
Pivot et al,
J Clin Onc 2015
CEREBEL126
Lapatinib+
capecitabine
(lap+ cap) vs
trastuzumab+
capecitabine
(tras+ cap)
HER2 inhibitors
(lap, tras),
prodrug that
converts to
5-fluorouracil
(cap)
HER2+ metastatic
breast cancer
without CNS
metastases at
baseline
No brain
metastases at
baseline
Phase III, randomized
study, preventative
trial.
Study terminated
early
540 (271
lap+ cap and
269 tras+ cap)
Incidence of CNS
mets as first
site of relapse:
3% in the
lap+ cap and
5% in
tras+ cap,
difference not
statistically
significant
n/a 22.7 mo for
lap+ cap
and
27.3 mo for
tras+ cap
NSCLC
Bearz et al,
Lung Cancer
2010146
Pemetrexed Folate anti-
metabolite
NSCLC metastatic
to brain
71.8% received
prior brain
irradiation
Retrospective review 39 Not specified 38.4% 10 mo
Ceresoli et al,
Ann Oncol
2004147
Gefitinib EGFR inhibitor Unselected patients
with NSCLC
metastatic to
brain
2 groups: prior
WBRT (44%)
and no prior
WBRT (56%)
Phase II 41 Disease control
rate
(CR+ PR+ SD)
10% 5 mo
Wu et al,
Ann Oncol
2013 (CTONG-
0803)148
Erlotinib EGFR inhibitor East Asian patients
with
adenocarcinoma
or EGFR mutant
NSCLC,
asymptomatic
brain
metastases
(total 16.7%
mutation
positive)
35.4% received
prior WBRT
Phase II 48 PFS 58.3% systemic
+intracranial
RR
(intracranial
RR alone not
reported)
18.9 mo
[patients
with EGFR
mutant
disease
37.5 mo vs
EGFR
wild-type
18.4 mo vs
unknown
EGFR status
19.4 mo,
P-value .14]
Besse et al,
Clin Ca Res
2015117
Bevacziumab+
carboplatin and
paclitaxel
VEGF inhibitor
(bevacziumab),
alkylating
agent
(carboplatin),
taxane
(paclitaxel)
Unselected NSCLC
patients with
asymptomatic,
prevously
untreated brain
metastases
No prior treatment Phase II
(noncomparative
study with 2 arms
atlhough only the
bevacizuamb +
carboplatin and
paclitaxel arm
results reported)
67 in the B+ CP
arm
Investigator-
assessed
6-month PFS
rate
61.2% 16 mo
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NSCLC include a Phase II study of ceritinib for ALK-rearranged
BM and leptomeningeal disease.156 The randomized Phase III
ALEX trial comparing alectinib versus crizotinib in treatment-
naive patients with ALK-rearranged NSCLC allows enrollment
of patients with asymptomatic BM and leptomeningeal disease
and will measure time to CNS progression.157 Given the recent
approval of anti-PD1 antibodies as second-line therapy of both
squamous and nonsquamous NSCLC, further study of these
checkpoint inhibitors—alone158,159 or in combinations with
other agents160—in BM of NSCLC will also be pursued.
Conclusions and Future Directions
The clinical management and understanding of BM has
changed substantially in the last 5 years. Several of these
changes stem from improvements in systemic therapy, which
have led to better systemic control and longer patient OS, asso-
ciated with increased time at risk for developing BM. Being
aware of significant heterogeneity in prognosis and therapeutic
options for patients with BM is crucial for appropriate manage-
ment, with greater attention to developing individual patient
treatment plans based on predicted outcomes. The increase
in use of SRS alone for many patients with multiple BM is an
outgrowth of the desire to employ treatments focused on
local control while minimizing cognitive effects associated
with WBRT. Complications from BM and their treatment must
be considered in comprehensive patient management, espe-
cially with greater awareness that the majority of patients do
not die from their BM. Development of systemic therapies capa-
ble of preventing BM and controlling both intracranial and ex-
tracranial disease once BM are diagnosed is paramount. Many
clinical trials are under way to establish the efficacy of systemic
agents in BM, particularly for breast cancer, lung cancer, and
melanoma. Standardization of radiographic response criteria
and clinical trial design by the brain metastases working
group of RANO will hopefully provide more uniformity in assess-
ment of brain metastases and improve cross-trial comparison.
Future directions and challenges also include development of
drugs with better CNS penetration, earlier inclusion of BM pa-
tients in drug development, as well as increased understanding
of the molecular basis of BM and the role of chemoprevention
for BM.
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